Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 5/20 | 0.82 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350156 | 0.81 | TACR3 (0.57) | TACR3 | |
| SCHEMBL29972794 | 0.80 | TACR3 (0.56) | TACR3CCKARCCKBR | |
| SCHEMBL8019418 | 0.79 | OPRD1 (0.58) | — | |
| SCHEMBL29406603 | 0.78 | CTSB (0.54) | TACR3CCKARCCKBR | |
| SCHEMBL29351536 | 0.78 | OPRM1 (0.54) | TACR3CCKARCCKBR | |
| SCHEMBL2189862 | 0.77 | OPRM1 (0.55) | TACR3KEAP1 | |
| SCHEMBL11309694 | 0.76 | OPRM1 (0.52) | TACR3CCKARCCKBR | |
| SCHEMBL30209471 | 0.76 | OPRM1 (0.54) | TACR3CCKARKEAP1CCKBR | |
| SCHEMBL11309707 | 0.76 | OPRM1 (0.52) | TACR3CCKARCCKBR | |
| SCHEMBL29831896 | 0.76 | IL23R (0.55) | TACR3CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829556-A1 | NK-3 Receptor in vivo assay | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20070048225-A1 | NK3 receptor in vivo assay | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-01 | — | — | US | claimed |
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | disclosed |
| EP-4471032-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118715224-A | Acid salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115427412-B | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-112272670-B | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2023138681-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-4190784-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| CN-115427412-A | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022022680-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2020211798-A1 | INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE, AND PREPARATION METHOD AND USES THEREFOR | 上海翰森生物医药科技有限公司 | 2020-10-22 | — | — | WO | disclosed |
| US-10456439-B2 | NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation | ACADEMISCH MEDISCH CENTRUM (NL) | 2019-10-29 | — | — | US | disclosed |
| US-20190015471-A1 | NK3 AGONIST FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ATRIAL ARRHYTHMIA OR FIBRILLATION | Stichting Amsterdam UMC (NL) | 2019-01-17 | — | — | US | disclosed |
| EP-3206702-A1 | NK3 AGONIST FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ATRIAL ARRHYTHMIA OR FIBRILLATION | Academisch Medisch Centrum (NL) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016059191-A1 | NK3 AGONIST FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ATRIAL ARRHYTHMIA OR FIBRILLATION | ACADEMISCH MEDISCH CENTRUM (NL) | 2016-04-21 | — | — | WO | disclosed |
| EP-1829556-A1 | NK-3 Receptor in vivo assay | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20070048225-A1 | NK3 receptor in vivo assay | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, HSD17B11, CYP17A1 | TACR3 1362/4885CCKAR 550/4885KEAP1 2536/4885 |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, WEE1, SHBG | TACR3 1264/4885CCKAR 486/4885KEAP1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.